Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6746525
Reference Type
Journal Article
Title
The Utility of Administrative Data for Surveillance of Comorbidity in Multiple Sclerosis: A Validation Study
Author(s)
Marrie, RAnn; Tremlett, H; Fisk, J; Blanchard, JF; Yu, BoN; Leung, S; Elliott, L; Caetano, P; Warren, S; Wolfson, C; Patten, SB; Svenson, LW; ,
Year
2013
Is Peer Reviewed?
1
Journal
Neuroepidemiology
ISSN:
0251-5350
EISSN:
1423-0208
Publisher
KARGER
Location
BASEL
Page Numbers
85-92
PMID
23095571
DOI
10.1159/000343188
Web of Science Id
WOS:000314751700002
Abstract
Background: Although comorbidity is important in multiple sclerosis (MS), few validated methods for its assessment exist. We validated and applied administrative case definitions for several comorbidities in MS. Methods: Using provincial administrative data we identified persons with MS and a matched general population cohort. Case definitions for chronic lung disease (CLD), epilepsy, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and migraine were developed using administrative data, and validated against medical records. We applied these definitions to estimate the age-standardized prevalence of these comorbidities in the MS and matched cohorts. Results: Versus medical records, administrative case definitions showed moderate agreement for CLD (kappa = 0.41), migraine (kappa = 0.51), and epilepsy (kappa = 0.44), fair agreement for IBS (kappa = 0.36) and could not be calculated for IBD (small sample size). The 2005 prevalence of CLD was similar in the MS (15.6%) and general populations (14.4%). The prevalence of the remaining comorbidities was higher in the MS than the general populations: epilepsy (4.12 vs. 1.12%), IBD (0.78 vs. 0.65%), IBS (12.2 vs. 6.80%) and migraine (23.0 vs. 16.5%). Conclusions: Administrative data are valid for tracking CLD, epilepsy, and migraine in MS. The prevalence of epilepsy, IBD, IBS and migraine is increased in MS versus the general population. Copyright (C) 2012 S. Karger AG, Basel
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity